Lead Product(s) : Sapacitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : AstraZeneca | Cyclacel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2018
Lead Product(s) : Sapacitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : AstraZeneca | Cyclacel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sapacitabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 25, 2011
Lead Product(s) : Sapacitabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sapacitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2010
Lead Product(s) : Sapacitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : MD Anderson Cancer Center
Deal Size : Inapplicable
Deal Type : Inapplicable